Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury

被引:50
作者
Vink, R [1 ]
Van Den Heuvel, C [1 ]
机构
[1] Univ Adelaide, Med Sch N, Dept Pathol, Adelaide, SA 5005, Australia
基金
英国医学研究理事会;
关键词
cyclosporin A; dexamethasone; dexanabinol; magnesium; neuroprotection; neurotrauma; progesterone; traumatic brain injury;
D O I
10.1517/13543784.13.10.1263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Traumatic brain injury (TBI) is one of the leading causes of death and disability in the industrialised world and remains a major health problem with serious socioeconomic consequences. So far, despite encouraging preclinical results, almost all neuroprotection trials have failed to show any significant efficacy in the treatment of clinical TBI. This may be due, in part, to the fact that most of the therapies investigated have targeted an individual injury factor. It is now recognised that TBI is a very heterogeneous type of injury that varies widely in its aetiology, clinical presentation, severity and pathophysiology. The pathophysiological sequelae of TBI are mediated by an interaction of acute and delayed molecular, biochemical and physiological events that are both complex and multifaceted. Accordingly, a successful TBI treatment may have to simultaneously attenuate many injury factors. Recent efforts in experimental TBI have, therefore, focused on the development of neuropharmacotherapies that target multiple injury factors and thus improve the likelihood of a successful outcome. This review will focus on three such novel compounds that are currently being assessed in clinical trials; progesterone, dexanabinol and dexamethasone, and provide an update on the progress of both magnesium and cyclosporin A.
引用
收藏
页码:1263 / 1274
页数:12
相关论文
共 124 条
[1]  
ALDERSON P, 2004, COCHRANE LIB, V2
[2]   Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats [J].
Alessandri, B ;
Rice, AC ;
Levasseur, J ;
DeFord, M ;
Hamm, RJ ;
Bullock, MR .
JOURNAL OF NEUROTRAUMA, 2002, 19 (07) :829-841
[3]   Expression of the nuclear factor-κB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells:: Possible links to hypertension, atherogenesis, and stroke [J].
Altura, BM ;
Kostellow, AB ;
Zhang, AM ;
Li, WY ;
Morrill, GA ;
Gupta, RK ;
Altura, BT .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (09) :701-707
[4]   Low serum magnesium predicts neurological events in patients with advanced atherosclerosis [J].
Amighi, J ;
Sabeti, S ;
Schlager, O ;
Mlekusch, W ;
Exner, M ;
Lalouschek, W ;
Ahmadi, R ;
Minar, E ;
Schillinger, M .
STROKE, 2004, 35 (01) :22-27
[5]   DEXAMETHASONE PREVENTS HYPOXIC-ISCHEMIC BRAIN-DAMAGE IN THE NEONATAL RAT [J].
BARKS, JDE ;
POST, M ;
TUOR, UI .
PEDIATRIC RESEARCH, 1991, 29 (06) :558-563
[6]   Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury [J].
Baskaya, MK ;
Dogan, A ;
Rao, AM ;
Dempsey, RJ .
JOURNAL OF NEUROSURGERY, 2000, 92 (03) :448-452
[7]   HU-211, A NOVEL NONCOMPETITIVE N-METHYL-D-ASPARTATE ANTAGONIST, IMPROVES NEUROLOGICAL DEFICIT AND REDUCES INFARCT VOLUME AFTER REVERSIBLE FOCAL CEREBRAL-ISCHEMIA IN THE RAT [J].
BELAYEV, L ;
BUSTO, R ;
ZHAO, WZ ;
GINSBERG, MD .
STROKE, 1995, 26 (12) :2313-2319
[8]   Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury [J].
Büki, A ;
Okonkwo, DO ;
Povlishock, JT .
JOURNAL OF NEUROTRAUMA, 1999, 16 (06) :511-521
[9]   Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans [J].
Cernak, I ;
Savic, VJ ;
Kotur, J ;
Prokic, V ;
Veljovic, M ;
Grbovic, D .
JOURNAL OF NEUROTRAUMA, 2000, 17 (01) :53-68
[10]   Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events [J].
Clausen, T ;
Zauner, A ;
Levasseur, JE ;
Rice, AC ;
Bullock, R .
BRAIN RESEARCH, 2001, 908 (01) :35-48